Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 4.2 First Supplemental Indenture - Penwest Pharmaceuticals Co.
- 4.3 Second Supplemental Indenture - Generics Bidco I, LLC
- 4.4 Third Supplemental Indenture - Ledgemont Royalty Sub LLC
- 4.5 Fourth Supplemental Indenture - Vintage Pharmaceuticals, LLC
- 4.6 Fifth Supplemental Indenture - American Medical Systems Holdings, Inc.
- 4.7 Sixth Supplemental Indenture - American Medical Systems, Inc.
- 4.8 Seventh Supplemental Indenture - Generics Bidco II, LLC
- 4.11 First Supplemental Indenture - American Medical Systems Holdings, Inc.
- 4.12 Second Supplemental Indenture - American Medical Systems, Inc.
- 4.13 Third Supplemental Indenture - Generics Bidco II, LLC
- 4.16 First Supplemental Indenture - American Medical Systems Holdings, Inc.
- 4.17 Second Supplemental Indenture - American Medical Systems, Inc.
- 4.18 Third Supplemental Indenture - Generics Bidco II, LLC
- 5 Opinion of Skadden, Arps, Slate, Meagher & Flom LLP
- 12 Statement Regarding Computation of Ratio of Earnings to Fixed Charges
- 21 Subsidiaries of the Registrant
- 23.1 Consent of Independent Registered Public Accounting Firm
- 23.2 Consent of Independent Registered Public Accounting Firm
- 23.3 Consent of Independent Registered Public Accounting Firm
- 25.1 Statement of Eligibility of Trustee, Indenture for 7.00% Senior Notes Due 2020
- 25.2 Statement of Eligibility of Trustee, Indenture for 7% Senior Notes Due 2019
- 25.3 Statement of Eligibility of Trustee, Indenture for 7 1/4% Senior Notes Due 2022
- 99.1 Form of Letter of Transmittal
- 99.2 Form of Letter to Clients
- 99.3 Form of Letter to Brokers
AMS Sales similar filings
Filing view
External links
Exhibit 23.3
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” in the Registration Statement (Form S-4) and related Prospectus for the exchange of senior notes, of Endo Pharmaceuticals Holdings, Inc. and to the incorporation by reference therein of our report dated March 26, 2010, with respect to the consolidated financial statements of Generics International (US), Inc and subsidiaries for the year ended December 31, 2009, included in its Current Report on Form 8-K of Endo Pharmaceuticals Holdings, Inc. filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Metro Park, New Jersey
October 14, 2011